

References

L-164

1. National Comprehensive Cancer Network: Practice Guidelines in Oncology 4.2016. Non- Small Cell Lung Cancer. Available at www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
2. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non–small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. *J Clin Oncol*. Published online ahead of print, April 11, 2011. Available at jco.ascopubs.org/cgi/doi/10.1200/JCO.2010.31.8923.
3. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. *N Eng J Med*. 2005;353:133-44.
4. Lindeman N, Cagle P, Ladanyi M, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Archives Of Pathology & Laboratory Medicine*. June 2013;137(6):828-860.
5. FDA. Table of valid genomic biomarkers in the context of approved drug labels. Available at www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
6. Erlotinib (Tarceva®) prescribing Information. San Francisco, CA 94080-4990: Genentech Oncology. Available at www.gene.com/gene/products/information/pdf/tarcevaprescribing.pdf. Revised April 2010.
7. Gefitinib (Iressa®) prescribing Information. Wilmington, DE 19850: Astra Zeneca Pharmaceuticals. Available at www.azpicentral.com/iressa/iressa.pdf
8. Afatinib (Gilotrif®) prescribing information. Ridgefield, CT 06877: Boehringer Ingelheim International GmbH. Available at www.gilotrif.com/content/dam/internet/pm/gilotrif4/com_EN/documents/Gilotrif.pdf.

9. Lab Management Guidelines V2.0.2017